Literature DB >> 6249870

Microneutalization of cytomegalovirus.

H Stalder, A Ehrensberger.   

Abstract

A simple microneutralization test for cytomegalovirus (CMV) is presented. Using a laboratory adapted stock virus, definite results were obtained after 10 days. All patients with primary CMV infection showed an antibody rise and/or seroconversion; however, neutralizing antibody appeared only seven weeks after the onset of clinical symptoms. In control patients without evidence of recent primary infection, there was a complete concordance of the presence of complement-fixing and neutralizing antibodies.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6249870     DOI: 10.1093/infdis/142.1.102

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  6 in total

Review 1.  Molecular biology and immunology of cytomegalovirus.

Authors:  P D Griffiths; J E Grundy
Journal:  Biochem J       Date:  1987-01-15       Impact factor: 3.857

2.  Evaluation of immunoglobulin G preparations for anti-cytomegalovirus antibodies with reference to neutralizing antibody in the presence of complement.

Authors:  Y Eizuru; I Ueno; Y Minamishima
Journal:  J Clin Microbiol       Date:  1988-09       Impact factor: 5.948

3.  Cytomegalovirus early and late membrane antigens detected by antibodies in human convalescent sera.

Authors:  J M Middeldorp; J Jongsma; T H The
Journal:  J Virol       Date:  1985-04       Impact factor: 5.103

4.  Rapid neutralization assay for human cytomegalovirus antibody.

Authors:  M Zerbini; M Plazzi; M Musiani
Journal:  J Clin Microbiol       Date:  1985-06       Impact factor: 5.948

Review 5.  Diagnosis and management of human cytomegalovirus infection in the mother, fetus, and newborn infant.

Authors:  Maria Grazia Revello; Giuseppe Gerna
Journal:  Clin Microbiol Rev       Date:  2002-10       Impact factor: 26.132

6.  Mouse cytomegalovirus is infectious for rats and alters lymphocyte subsets and spleen cell proliferation.

Authors:  C B Smith; L S Wei; M Griffiths
Journal:  Arch Virol       Date:  1986       Impact factor: 2.574

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.